U.S. Markets closed

Biogennix Names Michael Roux General Manager

IRVINE, Calif.--(BUSINESS WIRE)--

Company Also Expands Sales, Marketing and R&D Teams

Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft substitutes used for bone fusion procedures, has named Michael Roux its new General Manager.

With nearly three decades of successful technology and medical device industry experience, Roux most recently led Product Management at Glidewell Laboratories, a leading dental products technology company. Previously, he served as Vice President of Product Management with Patient Safety Technologies, acquired by Stryker in 2014. Roux also spent time as a Global Director at Hill-Rom, as well as 3M, where he held positions of increasing responsibility within product engineering, six-sigma, global product marketing, and business development.

Roux holds a B.S. in Industrial Engineering from the University of Minnesota, and an MBA in Marketing from the University of St. Thomas.

“Michael brings significant business, medical device and marketing leadership experience to our team, positioning Biogennix for the next level of growth,” said Clay Shors, Biogennix’s President. “He has a strong background in product management and marketing with a wide range of medical device and multi-national business expertise with leading publicly-owned and privately held companies. We look forward to reaping the benefits of his ability to consistently deliver bottom line results in entrepreneurial to large scale global businesses through strategic thinking, data driven decision making, innovative problem solving, effective team building and leadership.”

In full growth mode, Biogennix has also expanded its sales, marketing and R&D teams with some key additions: Jennifer Sorenson, Valerie Powers, and Savvas Papanicolaou.

Earlier last month, Jennifer Sorenson was named Regional Vice President of Sales for Biogennix. Sorenson, based out of the Dallas-Fort Worth region, brings close to two decades of sales leadership experience, with an extensive background in the spine, biologics and orthopedics markets. Valerie Powers, Biogennix’s new Marketing Manager, brings a unique blend of clinical and marketing expertise from over a decade of hospital and medical device experience, including stints at UCLA Health, St. Joseph’s Health, Edwards Lifesciences, and various medical start-ups. Also, Savvas Papanicolaou, Biogennix’s new Senior Project Engineer, brings over a decade of successful lead engineering and product design and development experience from UC Davis Health, as well as other leading orthopedic manufacturers.

Shors noted that with the addition of Roux, the other new team members and several expanded sales and marketing initiatives for 2019, Biogennix expects to continue to grow exponentially and expand upon 2018’s success.

The majority of Biogennix’s year over year growth to date is attributed to steady increases in sales of the company’s novel bone graft substitutes, Morpheus™ and osteoSPAN™, both of which are resorbable, osteoconductive scaffolds ideally suited for bone regeneration. The Morpheus product is a moldable version of osteoSPAN, which combines the granules with an organic binder, providing optimal handling characteristics for surgeons.

Biogennix is a leading developer of osteobiologic products specifically designed for spine fusion and bone trauma. The company is led by a team of scientists and industry veterans committed to delivering unique products for bone regeneration. Biogennix designs, manufactures and distributes all of its products from its Irvine-based facilities.

Biogennix is a fully-integrated osteobiologic company headquartered in Irvine which develops, manufactures, and distributes proprietary bone graft substitutes used in bone fusion procedures. Learn more at biogennix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005799/en/